Evidence map›Paper›PMID 23663568›Full record

ArticleJournal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale2013

Primary surgery versus chemoradiotherapy for advanced oropharyngeal cancers: a longitudinal population study.

Daniel O'Connell, Hadi Seikaly, Russell Murphy, Charles Fung, Tim Cooper, Aaron Knox, Rufus Scrimger, Jeffrey R Harris

Registry-linked trialOpen access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05144100 (Primary Surgery Vs Primary Chemoradiation for Oropharyngeal Cancer), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05144100 phase2 / phase3not yet recruitingnot on this mapstarted 2021, after this paper: background citation

Primary Surgery Vs Primary Chemoradiation for Oropharyngeal Cancer (Scope Trial) - A Phase II/III Integrated Design Randomized Control Trial

TypeinterventionalSponsorTata Memorial CentreRan2021 to 2031Enrolled498ConditionsStage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8ArmsSurgery with or without Neck Dissection, Radiation, Cisplatin based chemotherpay
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The impact of human papillomavirus (HPV) status on functional outcomes and quality of life (QOL) after surgical treatment of oropharyngeal carcinoma with free-flap reconstruction.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2018
    Article
  8. Article
  9. Article
  10. Article
  11. Transoral robotic surgery with radial forearm free flap reconstruction: case control analysis.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2017
    Article
  12. Article
  13. Article
  14. Correlation of PET-CT nodal SUVmax with p16 positivity in oropharyngeal squamous cell carcinoma.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2015
    Article
  15. A different entity: a population based study of characteristics and recurrence patterns in oropharyngeal squamous cell carcinomas.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2015
    Article
  16. Survival outcomes of First Nations patients with oral cavity squamous cell carcinoma (Poliquin 2014).Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2015
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Daniel O'ConnellDivision of Otolaryngology-Head & Neck Surgery, University of Alberta, Edmonton, AB, Canada.
Hadi SeikalyDivision of Otolaryngology-Head & Neck Surgery, University of Alberta, Edmonton, AB, Canada.
Russell MurphyDivision of Otolaryngology-Head & Neck Surgery, University of Alberta, Edmonton, AB, Canada.
Charles FungFaculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Tim CooperFaculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Aaron KnoxFaculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Rufus ScrimgerDivision of Radiation Oncology, University of Alberta, Edmonton, AB, Canada.
Jeffrey R HarrisDivision of Otolaryngology-Head & Neck Surgery, University of Alberta, Edmonton, AB, Canada ; 1E4.29 Walter C. MacKenzie Health Sciences Centre, 8440 112 Street, Edmonton, AB T6G 1B7, Canada.
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment for advanced stage oropharyngeal squamous cell carcinoma (OPSCC) includes combined chemoradiation therapy or surgery followed by radiation therapy alone or in combination with chemotherapy. The goal of this study was to utilize available evidence to examine survival outcome differences in patients with advanced stage OPSCC treated with these different modalities.

methodsPatients with advanced stage OPSCC were identified. Primary outcome measurements were disease specific and overall survival rates with differences examined via Kaplan-Meier and logistic regression analysis.

results344 patients were enrolled. 94 patients underwent triple modality therapy inclusive of surgery followed by adjuvant combined chemotherapy and radiation therapy (S-CRT). 131 had surgery and radiation therapy (S-RT), while 56 had chemoradiation (CRT) therapy as their primary treatment. A total of 63 patients had single modality radiation therapy and were excluded from analysis due to the large number of palliative patients. Kaplan-Meier overall survival analysis showed that therapy with S-CRT had the highest disease specific survival at five years (71.1%). This is contrasted against S-RT and CRT, with five year survival rates at 53.9%, and 48.6%, respectively. Cox regression showed that the comparison of S-CRT vs. S-RT, and CRT is associated with statistically significant increased hazard ratios of 1.974, and 2.785, indicating that both S-RT and CRT are associated with a reduced likelihood of survival at 5 years when compared to S-CRT.

conclusionsIn this population based cohort study S-CRT is associated with a 17-22% 5 year disease specific survival benefit compared to CRT or S-RT.

Indexed as

Cause of DeathChemoradiotherapyCross-Sectional StudiesDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLongitudinal StudiesMaleNeoplasm InvasivenessNeoplasm StagingOropharyngeal NeoplasmsOropharynxPrognosisProportional Hazards ModelsSurvival Analysis

Identifiers

PMID23663568
PMCPMC3668157
OpenAlexW2116366751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.